Papillary Thyroid Cancer Prognosis: An Evolving Field

Over the last few years, a great advance has been made in the comprehension of the molecular pathogenesis underlying thyroid cancer progression, particularly for the papillary thyroid cancer (PTC), which represents the most common thyroid malignancy. Putative cancer driver mutations have been identi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, Antonio Catania, Filippo Maria Di Matteo, Flavio Forte, Alberto Santoro, Piergaspare Palumbo, Vito D’Andrea, Salvatore Sorrenti
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	thyroid cancers molecular pathogenesis prognosis therapy TNM tumor molecular profiling Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/55dd12b4951f49a08a6be3eedaf75e4d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55dd12b4951f49a08a6be3eedaf75e4d
record_format	dspace
spelling	oai:doaj.org-article:55dd12b4951f49a08a6be3eedaf75e4d2021-11-11T15:35:25ZPapillary Thyroid Cancer Prognosis: An Evolving Field10.3390/cancers132155672072-6694https://doaj.org/article/55dd12b4951f49a08a6be3eedaf75e4d2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5567https://doaj.org/toc/2072-6694Over the last few years, a great advance has been made in the comprehension of the molecular pathogenesis underlying thyroid cancer progression, particularly for the papillary thyroid cancer (PTC), which represents the most common thyroid malignancy. Putative cancer driver mutations have been identified in more than 98% of PTC, and a new PTC classification into molecular subtypes has been proposed in order to resolve clinical uncertainties still present in the clinical management of patients. Additionally, the prognostic stratification systems have been profoundly modified over the last decade, with a view to refine patients’ staging and being able to choose a clinical approach tailored on single patient’s needs. Here, we will briefly discuss the recent changes in the clinical management of thyroid nodules, and review the current staging systems of thyroid cancer patients by analyzing promising clinicopathological features (i.e., gender, thyroid auto-immunity, multifocality, PTC histological variants, and vascular invasion) as well as new molecular markers (i.e., BRAF/TERT promoter mutations, miRNAs, and components of the plasminogen activating system) potentially capable of ameliorating the prognosis of PTC patients.Salvatore UlisseEnke BaldiniAugusto LauroDaniele PironiDomenico TripodiEleonora LoriIulia Catalina FerentMaria Ida AmabileAntonio CataniaFilippo Maria Di MatteoFlavio ForteAlberto SantoroPiergaspare PalumboVito D’AndreaSalvatore SorrentiMDPI AGarticlethyroid cancersmolecular pathogenesisprognosistherapyTNMtumor molecular profilingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5567, p 5567 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	thyroid cancers molecular pathogenesis prognosis therapy TNM tumor molecular profiling Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	thyroid cancers molecular pathogenesis prognosis therapy TNM tumor molecular profiling Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Salvatore Ulisse Enke Baldini Augusto Lauro Daniele Pironi Domenico Tripodi Eleonora Lori Iulia Catalina Ferent Maria Ida Amabile Antonio Catania Filippo Maria Di Matteo Flavio Forte Alberto Santoro Piergaspare Palumbo Vito D’Andrea Salvatore Sorrenti Papillary Thyroid Cancer Prognosis: An Evolving Field
description	Over the last few years, a great advance has been made in the comprehension of the molecular pathogenesis underlying thyroid cancer progression, particularly for the papillary thyroid cancer (PTC), which represents the most common thyroid malignancy. Putative cancer driver mutations have been identified in more than 98% of PTC, and a new PTC classification into molecular subtypes has been proposed in order to resolve clinical uncertainties still present in the clinical management of patients. Additionally, the prognostic stratification systems have been profoundly modified over the last decade, with a view to refine patients’ staging and being able to choose a clinical approach tailored on single patient’s needs. Here, we will briefly discuss the recent changes in the clinical management of thyroid nodules, and review the current staging systems of thyroid cancer patients by analyzing promising clinicopathological features (i.e., gender, thyroid auto-immunity, multifocality, PTC histological variants, and vascular invasion) as well as new molecular markers (i.e., BRAF/TERT promoter mutations, miRNAs, and components of the plasminogen activating system) potentially capable of ameliorating the prognosis of PTC patients.
format	article
author	Salvatore Ulisse Enke Baldini Augusto Lauro Daniele Pironi Domenico Tripodi Eleonora Lori Iulia Catalina Ferent Maria Ida Amabile Antonio Catania Filippo Maria Di Matteo Flavio Forte Alberto Santoro Piergaspare Palumbo Vito D’Andrea Salvatore Sorrenti
author_facet	Salvatore Ulisse Enke Baldini Augusto Lauro Daniele Pironi Domenico Tripodi Eleonora Lori Iulia Catalina Ferent Maria Ida Amabile Antonio Catania Filippo Maria Di Matteo Flavio Forte Alberto Santoro Piergaspare Palumbo Vito D’Andrea Salvatore Sorrenti
author_sort	Salvatore Ulisse
title	Papillary Thyroid Cancer Prognosis: An Evolving Field
title_short	Papillary Thyroid Cancer Prognosis: An Evolving Field
title_full	Papillary Thyroid Cancer Prognosis: An Evolving Field
title_fullStr	Papillary Thyroid Cancer Prognosis: An Evolving Field
title_full_unstemmed	Papillary Thyroid Cancer Prognosis: An Evolving Field
title_sort	papillary thyroid cancer prognosis: an evolving field
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/55dd12b4951f49a08a6be3eedaf75e4d
work_keys_str_mv	AT salvatoreulisse papillarythyroidcancerprognosisanevolvingfield AT enkebaldini papillarythyroidcancerprognosisanevolvingfield AT augustolauro papillarythyroidcancerprognosisanevolvingfield AT danielepironi papillarythyroidcancerprognosisanevolvingfield AT domenicotripodi papillarythyroidcancerprognosisanevolvingfield AT eleonoralori papillarythyroidcancerprognosisanevolvingfield AT iuliacatalinaferent papillarythyroidcancerprognosisanevolvingfield AT mariaidaamabile papillarythyroidcancerprognosisanevolvingfield AT antoniocatania papillarythyroidcancerprognosisanevolvingfield AT filippomariadimatteo papillarythyroidcancerprognosisanevolvingfield AT flavioforte papillarythyroidcancerprognosisanevolvingfield AT albertosantoro papillarythyroidcancerprognosisanevolvingfield AT piergasparepalumbo papillarythyroidcancerprognosisanevolvingfield AT vitodandrea papillarythyroidcancerprognosisanevolvingfield AT salvatoresorrenti papillarythyroidcancerprognosisanevolvingfield
_version_	1718435178540433408

Papillary Thyroid Cancer Prognosis: An Evolving Field

Ejemplares similares